Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

[1]  R. Kryscio,et al.  Transvaginal sonography as a screening method for the detection of early ovarian cancer. , 1997, Gynecologic oncology.

[2]  L. Smith,et al.  Detection of malignant ovarian neoplasms: a review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. , 1984, Obstetrical & gynecological survey.

[3]  Yoshiharu Saito,et al.  Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography , 2000 .

[4]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[5]  M. Metra,et al.  Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. , 2003, Journal of the American College of Cardiology.

[6]  C. Mangioni,et al.  Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  David Haber,et al.  Guide to clinical preventive services: a challenge to physician resourcefulness , 1993 .

[8]  J. Murdoch,et al.  The surgical management of women with ovarian cancer in the south west of England , 2001, British Journal of Cancer.

[9]  P. Prorok,et al.  Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. , 2000, American journal of obstetrics and gynecology.

[10]  E J Pavlik,et al.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. , 2000, Gynecologic oncology.

[11]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[12]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[13]  Steven J Skates,et al.  Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D B Matchar,et al.  The Effectiveness of Ovarian Cancer Screening: A Decision Analysis Model , 1993, Annals of Internal Medicine.

[15]  D. Hole,et al.  Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients , 1999, British journal of obstetrics and gynaecology.

[16]  I. Jacobs,et al.  Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study , 1996, BMJ.

[17]  R. Bast,et al.  Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer , 1992, Obstetrics and gynecology.

[18]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis , 2002 .

[19]  John K. Gohagan,et al.  The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial , 2000 .

[20]  M. Sherman,et al.  Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States , 2002, Cancer.